Skip main navigation
Close Drawer MenuOpen Drawer Menu
×

Randomized Ablation-Based Rhythm-Control Versus Rate-Control Trial in Patients With Heart Failure and Atrial Fibrillation: Results from the RAFT-AF trial

Originally published22 Mar 2022https://doi.org/10.1161/CIRCULATIONAHA.121.057095Circulation. 2022;145:1693–1704

Abstract

Background:

Atrial fibrillation (AF) and heart failure (HF) frequently coexist and can be challenging to treat. Pharmacologically based rhythm control of AF has not proven to be superior to rate control. Ablation-based rhythm control was compared with rate control to evaluate if clinical outcomes in patients with HF and AF could be improved.

Methods:

This was a multicenter, open-label trial with blinded outcome evaluation using a central adjudication committee. Patients with high-burden paroxysmal (>4 episodes in 6 months) or persistent (duration <3 years) AF, New York Heart Association class II to III HF, and elevated NT-proBNP (N-terminal pro brain natriuretic peptide) were randomly assigned to ablation-based rhythm control or rate control. The primary outcome was a composite of all-cause mortality and all HF events, with a minimum follow-up of 2 years. Secondary outcomes included left ventricular ejection fraction, 6-minute walk test, and NT-proBNP. Quality of life was measured using the Minnesota Living With Heart Failure Questionnaire and the AF Effect on Quality of Life. The primary analysis was time-to-event using Cox proportional hazards modeling. The trial was stopped early because of a determination of apparent futility by the Data Safety Monitoring Committee.

Results:

From December 1, 2011, to January 20, 2018, 411 patients were randomly assigned to ablation-based rhythm control (n=214) or rate control (n=197). The primary outcome occurred in 50 (23.4%) patients in the ablation-based rhythm-control group and 64 (32.5%) patients in the rate-control group (hazard ratio, 0.71 [95% CI, 0.49–1.03]; P=0.066). Left ventricular ejection fraction increased in the ablation-based group (10.1±1.2% versus 3.8±1.2%, P=0.017), 6-minute walk distance improved (44.9±9.1 m versus 27.5±9.7 m, P=0.025), and NT-proBNP demonstrated a decrease (mean change –77.1% versus –39.2%, P<0.0001). Minnesota Living With Heart Failure Questionnaire demonstrated greater improvement in the ablation-based rhythm-control group (least-squares mean difference of –5.4 [95% CI, –10.5 to –0.3]; P=0.0036), as did the AF Effect on Quality of Life score (least-squares mean difference of 6.2 [95% CI, 1.7–10.7]; P=0.0005). Serious adverse events were observed in 50% of patients in both treatment groups.

Conclusions:

In patients with high-burden AF and HF, there was no statistical difference in all-cause mortality or HF events with ablation-based rhythm control versus rate control; however, there was a nonsignificant trend for improved outcomes with ablation-based rhythm control over rate control.

Registration:

URL: https://www.clinicaltrials.gov; Unique identifier: NCT01420393.

Footnotes

Supplemental Material, the podcast, and transcript are available with this article at https://www.ahajournals.org/doi/suppl/10.1161/CIRCULATIONAHA.121.057095.

Continuing medical education (CME) credit is available for this article. Go to http://cme.ahajournals.org to take the quiz.

For Sources of Funding and Disclosures, see page 1703.

https://www.ahajournals.org/journal/circ

Correspondence to: Ratika Parkash, MD, MSc, Queen Elizabeth II Health Sciences Centre, 1796 Summer Street, Room 2501A, Halifax, Nova Scotia, Canada B3H 3A7; Email
Anthony S.L. Tang, MD, C6-116, University Hospital, London Health Sciences Centre, 339 Windermere Road, London, Ontario N6A 5A5. Email

References

  • 1. Braunwald E. Shattuck lecture–cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities.N Engl J Med. 1997; 337:1360–1369. doi: 10.1056/NEJM199711063371906CrossrefMedlineGoogle Scholar
  • 2. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, Domanski M, Troutman C, Anderson J, Johnson G, et al.; Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.N Engl J Med. 2005; 352:225–237. doi: 10.1056/NEJMoa043399CrossrefMedlineGoogle Scholar
  • 3. Flaker GC, Blackshear JL, McBride R, Kronmal RA, Halperin JL, Hart RG. Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators.J Am Coll Cardiol. 1992; 20:527–532. doi: 10.1016/0735-1097(92)90003-6CrossrefMedlineGoogle Scholar
  • 4. Kaufman ES, Zimmermann PA, Wang T, Dennish GW, Barrell PD, Chandler ML, Greene HL; Atrial Fibrillation Follow-up Investigation of Rhythm Management investigators. Risk of proarrhythmic events in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study: a multivariate analysis.J Am Coll Cardiol. 2004; 44:1276–1282. doi: 10.1016/j.jacc.2004.06.052MedlineGoogle Scholar
  • 5. Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, Kellen JC, Greene HL, Mickel MC, Dalquist JE, et al.; Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation.N Engl J Med. 2002; 347:1825–1833. doi: 10.1056/NEJMoa021328CrossrefMedlineGoogle Scholar
  • 6. Roy D, Talajic M, Nattel S, Wyse DG, Dorian P, Lee KL, Bourassa MG, Arnold JM, Buxton AE, Camm AJ, et al.; Atrial Fibrillation and Congestive Heart Failure Investigators. Rhythm control versus rate control for atrial fibrillation and heart failure.N Engl J Med. 2008; 358:2667–2677. doi: 10.1056/NEJMoa0708789CrossrefMedlineGoogle Scholar
  • 7. Khan MN, Jaïs P, Cummings J, Di Biase L, Sanders P, Martin DO, Kautzner J, Hao S, Themistoclakis S, Fanelli R, et al.; PABA-CHF Investigators. Pulmonary-vein isolation for atrial fibrillation in patients with heart failure.N Engl J Med. 2008; 359:1778–1785. doi: 10.1056/NEJMoa0708234CrossrefMedlineGoogle Scholar
  • 8. Kuck KH, Merkely B, Zahn R, Arentz T, Seidl K, Schlüter M, Tilz RR, Piorkowski C, Gellér L, Kleemann T, et al.. Catheter ablation versus best medical therapy in patients with persistent atrial fibrillation and congestive heart failure: the randomized AMICA trial.Circ Arrhythm Electrophysiol. 2019; 12:e007731. doi: 10.1161/CIRCEP.119.007731LinkGoogle Scholar
  • 9. MacDonald MR, Connelly DT, Hawkins NM, Steedman T, Payne J, Shaw M, Denvir M, Bhagra S, Small S, Martin W, et al.. Radiofrequency ablation for persistent atrial fibrillation in patients with advanced heart failure and severe left ventricular systolic dysfunction: a randomised controlled trial.Heart. 2011; 97:740–747. doi: 10.1136/hrt.2010.207340CrossrefMedlineGoogle Scholar
  • 10. Jones DG, Haldar SK, Hussain W, Sharma R, Francis DP, Rahman-Haley SL, McDonagh TA, Underwood SR, Markides V, Wong T. A randomized trial to assess catheter ablation versus rate control in the management of persistent atrial fibrillation in heart failure.J Am Coll Cardiol. 2013; 61:1894–1903. doi: 10.1016/j.jacc.2013.01.069CrossrefMedlineGoogle Scholar
  • 11. Hunter RJ, Berriman TJ, Diab I, Kamdar R, Richmond L, Baker V, Goromonzi F, Sawhney V, Duncan E, Page SP, et al.. A randomized controlled trial of catheter ablation versus medical treatment of atrial fibrillation in heart failure (the CAMTAF trial).Circ Arrhythm Electrophysiol. 2014; 7:31–38. doi: 10.1161/CIRCEP.113.000806LinkGoogle Scholar
  • 12. Di Biase L, Mohanty P, Mohanty S, Santangeli P, Trivedi C, Lakkireddy D, Reddy M, Jais P, Themistoclakis S, Dello Russo A, et al.. Ablation versus amiodarone for treatment of persistent atrial fibrillation in patients with congestive heart failure and an implanted device: results from the AATAC multicenter randomized trial.Circulation. 2016; 133:1637–1644. doi: 10.1161/CIRCULATIONAHA.115.019406LinkGoogle Scholar
  • 13. Prabhu S, Taylor AJ, Costello BT, Kaye DM, McLellan AJA, Voskoboinik A, Sugumar H, Lockwood SM, Stokes MB, Pathik B, et al.. Catheter ablation versus medical rate control in atrial fibrillation and systolic dysfunction: the CAMERA-MRI study.J Am Coll Cardiol. 2017; 70:1949–1961. doi: 10.1016/j.jacc.2017.08.041CrossrefMedlineGoogle Scholar
  • 14. Oral H, Pappone C, Chugh A, Good E, Bogun F, Pelosi F, Bates ER, Lehmann MH, Vicedomini G, Augello G, et al.. Circumferential pulmonary-vein ablation for chronic atrial fibrillation.N Engl J Med. 2006; 354:934–941. doi: 10.1056/NEJMoa050955CrossrefMedlineGoogle Scholar
  • 15. Parkash R, Tang AS, Sapp JL, Wells G. Approach to the catheter ablation technique of paroxysmal and persistent atrial fibrillation: a meta-analysis of the randomized controlled trials.J Cardiovasc Electrophysiol. 2011; 22:729–738. doi: 10.1111/j.1540-8167.2011.02010.xCrossrefMedlineGoogle Scholar
  • 16. Packer DL, Mark DB, Robb RA, Monahan KH, Bahnson TD, Poole JE, Noseworthy PA, Rosenberg YD, Jeffries N, Mitchell LB, et al.; CABANA Investigators. Effect of catheter ablation vs antiarrhythmic drug therapy on mortality, stroke, bleeding, and cardiac arrest among patients with atrial fibrillation: the CABANA randomized clinical trial.JAMA. 2019; 321:1261–1274. doi: 10.1001/jama.2019.0693CrossrefMedlineGoogle Scholar
  • 17. Marrouche NF, Brachmann J, Andresen D, Siebels J, Boersma L, Jordaens L, Merkely B, Pokushalov E, Sanders P, Proff J, et al.; CASTLE-AF Investigators. Catheter ablation for atrial fibrillation with heart failure.N Engl J Med. 2018; 378:417–427. doi: 10.1056/NEJMoa1707855CrossrefMedlineGoogle Scholar
  • 18. Parkash R, Wells G, Rouleau J, Talajic M, Essebag V, Skanes A, Wilton SB, Verma A, Healey JS, Tang AS. A randomized ablation-based atrial fibrillation rhythm control versus rate control trial in patients with heart failure and high burden atrial fibrillation: the RAFT-AF trial rationale and design.Am Heart J. 2021; 234:90–100. doi: 10.1016/j.ahj.2021.01.012CrossrefMedlineGoogle Scholar
  • 19. Ezekowitz JA, O’Meara E, McDonald MA, Abrams H, Chan M, Ducharme A, Giannetti N, Grzeslo A, Hamilton PG, Heckman GAet al.. 2017 comprehensive update of the Canadian Cardiovascular Society guidelines for the management of heart failure.Can J Cardiol. 2017; 33:1342–1433. doi: 10.1016/j.cjca.2017.08.022CrossrefMedlineGoogle Scholar
  • 20. Verma A, Cairns JA, Mitchell LB, Macle L, Stiell IG, Gladstone D, McMurtry MS, Connolly S, Cox JL, Dorian P, et al.; CCS Atrial Fibrillation Guidelines Committee. 2014 focused update of the Canadian Cardiovascular Society guidelines for the management of atrial fibrillation.Can J Cardiol. 2014; 30:1114–1130. doi: 10.1016/j.cjca.2014.08.001CrossrefMedlineGoogle Scholar
  • 21. Verma A, Novak P, Macle L, Whaley B, Beardsall M, Wulffhart Z, Khaykin Y. A prospective, multicenter evaluation of ablating complex fractionated electrograms (CFEs) during atrial fibrillation (AF) identified by an automated mapping algorithm: acute effects on AF and efficacy as an adjuvant strategy.Heart Rhythm. 2008; 5:198–205. doi: 10.1016/j.hrthm.2007.09.027CrossrefMedlineGoogle Scholar
  • 22. Gonzalez-Saenz de Tejada M, Bilbao A, Ansola L, Quiros R, Garcia-Perez L, Navarro G, Escobar A. Responsiveness and minimal clinically important difference of the Minnesota living with heart failure questionnaire.Health Qual Life Outcomes. 2019;17:36.CrossrefMedlineGoogle Scholar
  • 23. Spertus J, Dorian P, Bubien R, Lewis S, Godejohn D, Reynolds MR, Lakkireddy DR, Wimmer AP, Bhandari A, Burk C. Development and validation of the Atrial Fibrillation Effect on QualiTy-of-Life (AFEQT) Questionnaire in patients with atrial fibrillation.Circ Arrhythm Electrophysiol. 2011; 4:15–25. doi: 10.1161/CIRCEP.110.958033LinkGoogle Scholar
  • 24. Dorian P, Burk C, Mullin CM, Bubien R, Godejohn D, Reynolds MR, Lakkireddy DR, Wimmer AP, Bhandari A, Spertus J. Interpreting changes in quality of life in atrial fibrillation: how much change is meaningful?Am Heart J. 2013; 166:381–387.e8. doi: 10.1016/j.ahj.2013.04.015CrossrefMedlineGoogle Scholar
  • 25. Dorian P, Guerra PG, Kerr CR, O’Donnell SS, Crystal E, Gillis AM, Mitchell LB, Roy D, Skanes AC, Rose MS, et al.. Validation of a new simple scale to measure symptoms in atrial fibrillation: the Canadian Cardiovascular Society Severity in Atrial Fibrillation scale.Circ Arrhythm Electrophysiol. 2009; 2:218–224. doi: 10.1161/CIRCEP.108.812347LinkGoogle Scholar
  • 26. Multiple endpoints in clinical trials guidance for industry guidance for industry. FDA-2016-D-4460.Center for Biologics Evaluation and Research (CBER); January 2017.Google Scholar
  • 27. Wang W, Wang W, Mosley TH, Griswold ME. A SAS macro for the joint modeling of longitudinal outcomes and multiple competing risk dropouts.Comput Methods Programs Biomed. 2017; 138:23–30. doi: 10.1016/j.cmpb.2016.10.003CrossrefMedlineGoogle Scholar
  • 28. Lin DY, Wei LJ, Yang I, Ying Z. Semiparametric regression for the mean and rate functions of recurrent events.JR Stat Soc Series B Stat Methodol. 2000; 62:711–730.CrossrefGoogle Scholar
  • 29. Wilton SB, Fundytus A, Ghali WA, Veenhuyzen GD, Quinn FR, Mitchell LB, Hill MD, Faris P, Exner DV. Meta-analysis of the effectiveness and safety of catheter ablation of atrial fibrillation in patients with versus without left ventricular systolic dysfunction.Am J Cardiol. 2010; 106:1284–1291. doi: 10.1016/j.amjcard.2010.06.053CrossrefMedlineGoogle Scholar
Back to top